Evidence map›Paper›PMID 40656068›Full record

ReviewNeuroscience applied2024

Research progress of cell treatment strategy in Parkinson's disease.

Ying-Long Peng, Jinwei Chen, Hengxiao Hu, Wenxiong Liu, Weiye Liang, Jian Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuroscience applied, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying-Long PengDepartment of Neurobiology, School of Medicine, South China University of Technology, Guangzhou, China.
Jinwei ChenDepartment of Neurobiology, School of Medicine, South China University of Technology, Guangzhou, China.
Hengxiao HuDepartment of Neurobiology, School of Medicine, South China University of Technology, Guangzhou, China.
Wenxiong LiuDepartment of Neurobiology, School of Medicine, South China University of Technology, Guangzhou, China.
Weiye LiangDepartment of Neurobiology, School of Medicine, South China University of Technology, Guangzhou, China.
Jian WangDepartment of Neurobiology, School of Medicine, South China University of Technology, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a neurological disorder that often affects middle-aged and elderly people. It is primarily characterized by the degeneration of dopaminergic (DA) neurons in the ventral midbrain. Clinical therapy mostly relies on the holistic approach of pharmaceutical intervention and surgical procedures. Nevertheless, therapies might just alleviate symptoms temporarily and then result in notable adverse consequences, ultimately failing to produce a therapeutic outcome. Stem cells has the benefits of being capable of self-renewal and exhibiting multi-directional differentiation potential. This enables replacement of dysfunctional neurons and reconstruction of neural circuit, offering promise for the treatment of Parkinson's disease. This research examines and evaluates the fundamental principles, effectiveness, benefits, and drawbacks of various stem cell types in the treatment of Parkinson's disease. This review provides a concise summary of many potential processes by which stem cells might be effective in treating Parkinson's disease. The aim is to support ongoing research and clinical trials focused on using stem cells for the treatment of Parkinson's disease.

Indexed as

Parkinson's diseaseStem cellsStem cells therapyTransplantation

Identifiers

PMID40656068
PMCPMC12244092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.